


STATUS OF CLAIMS

In the Claims

The following is a marked-up version of the claims with the language that is underlined ("____") being added and the language that contains strikethrough ("—") being deleted:

1. (Previously Presented) A composition comprising a compound, pharmaceutically acceptable salt, or stereoisomer of Formula I, or mixtures thereof:



Formula I

wherein R₁ and R₂ are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ₁Z₂, wherein Z₁ and Z₂ are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S; with the proviso that when R₁ is hydrogen, R₂ is a group other than hydrogen and when R₁ is methyl, R₂ is a group other than methyl; and a pharmaceutically acceptable carrier.

2. (Cancelled)

3. (Previously Presented) The composition of claim 1, wherein the aryl and heteroaryl are substituted with at least one of a halogen, an alkyl, an alkenyl, and an alkynyl.


4. (Cancelled)

5. (Original) The composition of claim 1, wherein the pharmaceutically acceptable salt is derived from an inorganic acid or an organic acid, wherein the inorganic acid is selected from the group consisting of hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids; and the organic acid is selected from the group consisting of acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pantoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and trifluoroacetic acids.

6. (Original) The composition of claim 5, wherein the pharmaceutically acceptable salt is derived from hydrochloric acid.

7-13 (Cancelled)

14. (Currently Amended) A method for treatment of cancer involving inappropriate tyrosine kinase activity in a mammal in need of such treatment, said method comprising administering to said mammal a therapeutically effective amount of a compound, pharmaceutically acceptable salt, or stereoisomer of Formula I, or mixtures thereof:



Formula I

wherein R₁ and R₂ are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ₁Z₂, wherein Z₁ and Z₂ are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S; with the proviso that when R₁ is hydrogen, R₂ is a group other than hydrogen, wherein the cancer is selected from the group of cancers consisting of cancers of the breast, leukemia, colon, ovarian, renal, prostate, and lung.

15. (Original) The method of claim 14, with the proviso that when R₁ is methyl, R₂ is a group other than methyl.
16. (Previously Presented) The method of claim 14, wherein R₁ and R₂ are methyl.

17. (Original) The method of claim 14 in combination with a therapy selected from the group consisting of radiation therapy and chemotherapy.

18. (Cancelled)


19. (Currently Amended) The method of claim ~~18~~ 14, wherein the cancer is selected from the group consisting of chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL).

20. (Original) The method of claim 16, wherein the cancer is selected from the group consisting of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).


21. (Original) The method of claim 14, wherein the therapeutically effective amount is between about 0.1 mg/kg of body weight up to less than about 50 mg/kg of body weight per day.

22. (Original) The method of claim 21, wherein the therapeutically effective amount is between about 0.5 mg/kg of body weight to about 25 mg/kg of body weight per day.


23. (Previously Presented) A method for making the compound of claim 26 comprising reacting:



and



wherein PG is a protecting group, with




in the presence of a coupling catalyst for promoting amide bond formation, and removing the protecting groups.

24. (Original) The method of claim 23, wherein the coupling catalyst is a mixture of HBTU (O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate) or HATU (O-(7-Azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate); DIPEA (N,N-diisopropylethylamine); and HOBT (1-hydroxybenzotriazole).

25. (Original) The method of claim 23, wherein the deprotection step comprises the addition of a saturated solution of hydrochloric acid in methanol.

26. (Previously Presented) A compound, pharmaceutically acceptable salt, or stereoisomer of Formula I, or mixtures thereof:



Formula I

wherein R₁ and R₂ are independently selected from the group consisting of H; alkyl; alkenyl; alkynyl; halogen; aryl; heteroaryl containing N, O, or S; the aryl and heteroaryl may be further substituted with halogen, an alkyl, alkenyl, and alkynyl; NZ₁Z₂, wherein Z₁ and Z₂ are independently selected from the group consisting of H and alkyl; and (CO)Y wherein Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heteroaryl containing N, O, or S; with the proviso that when R₁ is hydrogen, R₂ is a group other than hydrogen; and when R₁ is methyl, R₂ is a group other than methyl.

27. (Previously Presented) The compound of claim 26, wherein the aryl and heteroaryl are substituted with at least one of a halogen, an alkyl, an alkenyl, and an alkynyl.

28-29 (Cancelled)

30. (Previously Presented) The method of claim 16, wherein the cancer is selected from the group of cancers consisting of cancers of the breast, leukemia, colon and lung.

31. (Previously Presented) The method of claim 14, wherein the cancer is selected from the group of cancers consisting of cancers of the breast, leukemia, colon and lung.